№ files_lp_3_process_7_102137
File format: docx
Character count: 8909
File size: 21 KB
Public health guidance outlining the purpose, registration process, follow-up schedule, data protection framework, and reporting procedures associated with the CDC’s smartphone-based post-COVID-19 vaccination monitoring system v-safe.
Year:
2021
Country:
United States
Subject:
COVID-19 vaccination monitoring and reporting of side effects
Document Type:
Public health informational guidance
Issuing Organization:
Centers for Disease Control and Prevention
Related Institutions:
Food and Drug Administration
Program Name:
v-safe After Vaccination Health Checker
Associated System:
Vaccine Adverse Event Reporting System (VAERS)
Target Audience:
Individuals vaccinated against COVID-19 in the United States
Access Requirements:
Smartphone with internet access
Participation Period:
Up to 12 months after final vaccine dose
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Theme:
Accessibility
Document Type:
Guide
Organization / Institution:
University of Delaware
Target Audience:
Instructors, students
Type of document:
Symptom assessment questionnaire
Title on document:
Menopause Symptom Checker
Source:
Greene Climacteric Scale
Format:
Structured checklist with rating scale
Assessment scale:
0–3 (Not at all, A little, Quite a bit, Extremely)
Symptoms covered:
Psychological, somatic, vasomotor, sexual, and urogenital symptoms
Data fields:
Name, Date, Email address, Symptom frequency ratings, Comments
Intended population:
Individuals experiencing menopausal symptoms
Purpose:
Self-reported evaluation of current symptom frequency
Year:
2026
Region / city:
Gloucestershire, United Kingdom
Topic:
Mental Health Support and Quality Assurance
Document Type:
Job Description
Organization:
Inclusion Gloucestershire
Role:
Expert by Experience – Quality Checker
Reports to:
Quality Checking Manager
Target Audience:
Individuals with lived experience of mental health issues
Key Responsibilities:
Conduct quality checks, gather feedback from service users, report findings, support safeguarding and health and safety
Required Experience:
Lived experience of serious mental illness, experience receiving mental health support, understanding of mental health conditions
Skills:
Communication, rapport building, confidentiality, observation, teamwork, professional conduct
Training:
Provided for safeguarding and health and safety
Travel Requirements:
Independent travel to service locations
Technology Requirements:
Use of Microsoft Teams or Zoom
Charity Number:
1171559
Year:
2021
Country:
Global
Topic:
COVID-19 vaccination during pregnancy
Document Type:
Supplementary material
Study Type:
Systematic review
Authors:
Not specified
Target Audience:
Researchers, healthcare professionals, policy makers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / city:
Massachusetts
Topic:
Health Care Personnel Vaccination
Document Type:
Report
Agency / Organization:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target Audience:
Health Care Personnel, Licensed Facilities in Massachusetts
Period of Validity:
Oct 1 2025 - Mar 31 2026
Approval Date:
N/A
Date of Last Update:
N/A
Type of document:
Official information for health professionals
Topic:
Respiratory syncytial virus vaccination in pregnancy
Vaccine name:
Abrysvo®
Target population:
Pregnant women
Gestational age for administration:
28–36 weeks of pregnancy
Country:
Australia
Health program:
National Immunisation Program
Availability under NIP:
From 3 February 2025
Notifiable disease status:
RSV notifiable in Victoria since 22 February 2022
Regulatory authority:
Therapeutic Goods Administration
Monitoring scheme:
Black Triangle Scheme
Related legislation:
Public Health and Wellbeing Act 2008
Intended audience:
Health professionals
Storage requirements:
+2°C to +8°C
Business Rules for Quality and Outcomes Framework (QOF) 2023/2024/24-25 Vaccination and Immunisation
Note:
Author
Version Date:
01/04/2023–01/04/2024
Version:
48.049.0
Year:
2023
Region / City:
England
Subject:
Quality and Outcomes Framework, Vaccination, Immunisation
Document Type:
Guidelines
Organization:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES)
Target Audience:
GP Practices, GP System Suppliers, NHS England
Effective Period:
01/04/2023 – 31/03/2025
Approval Date:
01/04/2023
Amendment History Date:
01/04/2021, 01/04/2022, 01/04/2023
Supporting Documents:
Version 1.6 of the supporting information document
Reference Documents:
NHS Digital TRUD, Primary Care Domain Reference Set Portal
Note:
Year
Topic:
Immunisation Training
Document Type:
Competency Assessment
Target Audience:
Health care professionals in training
Year:
2023
Region / City:
Australia
Topic:
Japanese encephalitis vaccination
Document Type:
Consent form
Organization / Institution:
Australian Government
Author:
Unknown
Target Audience:
Individuals receiving JE vaccination
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2022
Region / City:
Alameda County, California
Subject:
COVID-19 Community Based Mobile Vaccination Services
Document Type:
Addendum
Agency:
Alameda County Health Care Services Agency (HCSA)
Author:
Alameda County Health Care Services Agency (HCSA)
Target Audience:
Potential Bidders
Effective Period:
October 1, 2022 – June 30, 2023
Approval Date:
August 3, 2022
Amendment Date:
August 5, 2022
Year:
1968
Region / City:
United Kingdom
Topic:
Vaccination, Measles, Immunology
Document Type:
Educational Text
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Students, Health professionals
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2014-2015
Region / City:
United States
Topic:
Influenza Vaccination
Document Type:
Informational Guide
Organization / Institution:
Centers for Disease Control and Prevention (CDC)
Author:
[xxx]
Target Audience:
Pharmacists, Healthcare Providers, Retailers
Period of Validity:
Current influenza season
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2021
Region / City:
United States
Topic:
COVID-19 Vaccination Policy
Document Type:
Policy and Procedure Template
Organization:
Rural Health Clinics (RHC)
Author:
Nathan Baugh, NARHC Executive Director, Sarah Hohman, NARHC Director of Government Affairs
Target Audience:
Rural Health Clinics Staff
Effective Period:
Starting from November 5, 2021
Approval Date:
N/A
Date of Changes:
N/A
Year:
2023
Publication date:
27 April 2023
Update date:
3 May 2023
Journal:
Communicable Diseases Intelligence
Volume:
47
DOI:
10.33321/cdi.2023.47.21
Country:
Australia
Authors:
Yuanfei Anny Huang; Jean Li-Kim-Moy; Sanjay Jayasinghe; Clayton Chiu; Kristine Macartney; Bette Liu; Penelope Burns; Michelle Giles; Nigel Crawford on behalf of ATAGI
Organisation:
Australian Technical Advisory Group on Immunisation
Topic:
Herpes zoster vaccination
Vaccines discussed:
Zostavax (ZVL); Shingrix (RZV)
Immunisation program:
Australian National Immunisation Program
Target population:
Older adults; immunocompromised people
Document type:
Targeted review
Year:
2025
Region / city:
Northern Ireland
Subject:
Influenza vaccination
Document type:
Protocol
Organization / institution:
Public Health Agency (PHA)
Author:
Strategic Planning and Performance Group (SPPG)
Target audience:
Healthcare professionals
Period of validity:
1 September 2025 - 1 April 2026
Approval date:
03/09/25
Note:
Change history
Version 1.0:
New national protocol for inactivated influenza vaccine, 6 October 2021
Version 2.0:
Eligibility and vaccine details update for 2022-2023, 26 August 2022
Version 3.0:
Eligibility update for 2024-2025, 8 August 2024
Version 4.0:
Update with eligibility criteria for 2025-2026, 13 August 2025
Date of amendments:
Various
Expiration date:
1 April 2026
Year:
2023
Region / City:
Massachusetts
Topic:
Meningococcal disease, Vaccination requirements
Document type:
Health advisory
Institution:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target audience:
College and residential school students, Parents and legal guardians
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Year:
2021
Region / city:
Global
Theme:
COVID-19 Vaccination
Document Type:
Report
Organization:
World Health Organization
Author:
World Health Organization
Target Audience:
Governments, health officials, international organizations
Period Covered:
(DD/MM/YYYY - DD/MM/YYYY)
Date of Approval:
28 April 2021
Date of Changes:
N/A
Year:
2025
Region / City:
Northern Ireland
Topic:
COVID-19 vaccination, mRNA vaccines
Document Type:
Protocol
Organization / Institution:
Strategic Planning and Performance Group (SPPG), Public Health Agency (PHA)
Author:
Dr. Louise Herron, Mrs. Deirdre Ward, Mrs. Kathryn Turner
Target Audience:
Healthcare professionals administering COVID-19 mRNA vaccines
Period of Validity:
3 April 2025 to 30 June 2025
Approval Date:
3 April 2025
Note:
Change History
Version 1.0:
New national protocol for COVID-19 vaccines (adults) - 5 April 2024
Version 2.0:
Updated to reflect change in vaccine antigenic content - 16 September 2024
Version 3.0:
Updated eligibility criteria for Spring 2025 - 6 March 2025